Penny Stock InVivo Therapeutics Holdings Corp. (OTC: NVIV), developer of groundbreaking technologies for the treatment of spinal cord injuries, is to be spotlighted on Fox News next week. NVIV had a rough day yesterday having touched $2.94 intraday before closing more than $0.50 lower at $2.42, down -14.79% for the day.
NVIV was 9th of the Top 10 most traded OTC penny stock on Thursday having executed 790 trades worth $2,812,711 on volume of 1,112,126 shares.
NVIV One Month Stock Chart:
NVIV CEO, Frank Reynolds, is scheduled to appear on San Antonio’s Fox News First on KABB-TV on Wednesday, February 22 during their 7:00 AM (CST) newscast. Reynolds will discuss the scaffold and how it is expected to work in humans, as well as results from InVivo’s largest non-human primate study. Reynolds is also scheduled to appear the same day on San Antonio Living on WOAI-TV that airs from 10:00 to 11:00 AM (CST).
Having pioneered a new treatment platform for spinal cord injuries, InVivo Therapeutics treatment uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord, minimizing tissue from scarring while improving recovery and prognosis after a traumatic spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. NVIV was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, NVIV earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, Mass.
ShareFEB
